Paper42663270
Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study.
Abhishek A and 17 others. Health Technol Assess, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study. Papers, record 42663270. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42663270
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Monitoring | Major topic |
| Hematologic Tests | Major topic |
| Immunosuppressive Agents | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Cost-Benefit Analysis | |
| Cost-Effectiveness Analysis | |
| Mercaptopurine | |
| Methotrexate | |
| Models, Economic | |
| United Kingdom |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05458531 | Monitoring of Inflammatory Conditions | Derived from the trial | Yes |
Source ClinicalTrials.gov
References360
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21722149 | Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. | Aliment Pharmacol Ther | 2011 | https://conductscience.org/library/papers/21722149 | PubMed |
| 2 | 26905864 | A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. | Ann Rheum Dis | 2017 | https://conductscience.org/library/papers/26905864 | PubMed |
| 3 | 37431434 | Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD). | Rheumatol Adv Pract | 2023 | https://conductscience.org/library/papers/37431434 | PubMed |
| 4 | 28652663 | Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. | World J Gastroenterol | 2017 | https://conductscience.org/library/papers/28652663 | PubMed |
| 5 | 25351370 | Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. | Health Technol Assess | 2014 | https://conductscience.org/library/papers/25351370 | PubMed |
| 6 | 7851193 | Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. | Dig Dis Sci | 1995 | https://conductscience.org/library/papers/7851193 | PubMed |
| 7 | 28450313 | Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. | Ann Rheum Dis | 2017 | https://conductscience.org/library/papers/28450313 | PubMed |
| 8 | 9330927 | Long-term treatment of destructive rheumatoid arthritis with methotrexate. | J Rheumatol | 1997 | https://conductscience.org/library/papers/9330927 | PubMed |
| 9 | 20569501 | 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. | Arthritis Res Ther | 2010 | https://conductscience.org/library/papers/20569501 | PubMed |
| 10 | 16402217 | Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. | Rheumatol Int | 2006 | https://conductscience.org/library/papers/16402217 | PubMed |
| 11 | 30137552 | The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. | Rheumatology (Oxford) | 2019 | https://conductscience.org/library/papers/30137552 | PubMed |
| 12 | 19665644 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. | Lancet | 2009 | https://conductscience.org/library/papers/19665644 | PubMed |
| 13 | 31388915 | Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis. | J Gen Intern Med | 2019 | https://conductscience.org/library/papers/31388915 | PubMed |
| 14 | 11096165 | A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. | N Engl J Med | 2000 | https://conductscience.org/library/papers/11096165 | PubMed |
| 15 | 15882242 | Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. | Aliment Pharmacol Ther | 2005 | https://conductscience.org/library/papers/15882242 | PubMed |
| 16 | 7872274 | Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. | Am J Gastroenterol | 1995 | https://conductscience.org/library/papers/7872274 | PubMed |
| 17 | 35702565 | Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. | Rheumatol Adv Pract | 2022 | https://conductscience.org/library/papers/35702565 | PubMed |
| 18 | 24609758 | Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. | Clin Rheumatol | 2014 | https://conductscience.org/library/papers/24609758 | PubMed |
| 19 | 27484275 | British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. | Br J Dermatol | 2016 | https://conductscience.org/library/papers/27484275 | PubMed |
| 20 | 35256384 | Persistently normal blood tests in patients taking methotrexate for RA or azathioprine for IBD: a retrospective cohort study. | Br J Gen Pract | 2022 | https://conductscience.org/library/papers/35256384 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42663270
GET https://conductscience.org/api/papers/v1/42663270/references?page=2